TABLE 1.
Respondent characteristics.
| # | Sex | Age range | Diagnosis | Psychiatric comorbidity | Depression treatment history | # Esketamine sessions |
| P1 | F | 60–65 | MDD | PD-NOS | - Multiple psychotherapies - Multiple ADs (SSRIs, SNRIs, TCAs) |
15 |
| P2 | M | 30–35 | MDD | – | -Multiple ADs (SSRI, SNRI, MAOI, lithium), bupropion -ECT, rTMS |
11 |
| P3 | F | 45–50 | MDD | APD PTSD symptoms |
-Multiple psychotherapies -Multiple ADs (SSRIs, SNRI, TCAs, mirtazapine, lithium and quetiapine addition), bupropion -ECT |
22 |
| P4 | F | 35–40 | BPD II | C-PTSD | -Multiple ADs (SSRIs, SNRIs, TCAs), bupropion, multiple mood stabilizers | 62 |
| P5 | M | 55–60 | MDD | ASS | -Multiple ADs (SSRIs, SNRIs, TCAs, MAOIs, lithium addition, antipsychotics addition) -ECT |
22 |
| P6 | F | 40–45 | MDD | – | -Multiple ADs (SSRIs, SNRIs, TCAs), bupropion -Multiple psychotherapies |
11 |
| P7 | M | 55–60 | MDD | – | -Multiple ADs (SSRIs, SNRIs, TCAs, lithium addition) -Multiple psychotherapies |
12 |
| P8 | M | 40–45 | BPD I | – | -Multiple ADs (SSRIs, SNRIs, TCA, lithium addition) -Multiple psychotherapies |
16 |
| P9 | F | 60–65 | MDD | – | -Multiple ADs (SSRIs, SNRIs, TCA + lithium addition) | 23 |
| P10 | F | 50–55 | MDD | ASS, PTSD | -Multiple ADs (SSRIs, SNRIs, TCA, MAOIs, lithium addition, antipsychotics addition) -EMDR, ECT |
24 |
| P11 | F | 60–65 | MDD | – | -Multiple ADs (SSRIs, SNRIs, TCAs, MAOIs, lithium addition) -Multiple psychotherapies -ECT |
316 |
| P12 | M | 55–60 | MDD | – | -Multiple ADs (SSRIs, SNRIs, TCAs, MAOIs, mirtazapine, lithium addition, antipsychotics addition), topiramate -EMDR |
90 |
| P13 | F | 60–65 | MDD | – | -Multiple ADs (SSRIs, SNRIs, TCAs, MAOIs, lithium addition, antipsychotics addition) -Multiple psychotherapies -ECT |
350 |
| P14 | F | 50–55 | MDD | – | -Multiple ADs (SSRIs, SNRIs, TCAs, MAOIs, lithium addition, antipsychotics addition) -Multiple psychotherapies |
∼65 |
| P15 | M | 40–45 | BPD I | ADHD, Migraine headaches | -Multiple ADs (SSRIs, SNRIs, TCAs, MAOIs, mirtazapine, lithium addition, antipsychotics addition) -ECT, Light therapy |
∼45 |
| P16 | F | 40–45 | MDD | ASS | -Multiple ADs (SSRIs, SNRIs, TCAs, MAOIs, lithium addition, antipsychotics addition) -Multiple psychotherapies -ECT, IV esketamine |
28 |
| P17 | F | 60–65 | MDD | – | -Multiple ADs (SSRIs, SNRIs, TCAs, MAOIs, lithium addition, antipsychotics addition) -Multiple psychotherapies |
12 |
ADs, antidepressants; ADHD, attention deficit hyperactivity disorder; APD, avoidant personality disorder; ASS, autism spectrum disorder; BPD, bipolar disorder; EMDR, eye movement desensitization and reprocessing; ECT, electroconvulsive therapy; MAOis, monoamine oxidase inhibitors; MDD, major depressive disorder; PD-NOS, personality disorder not otherwise specified; PTSD, post-traumatic stress disorder; SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.